The influence of selective serotonin reuptake inhibitors on the plasma and brain pharmacokinetics of the simplest phenothiazine neuroleptic promazine in the rat

European Neuropsychopharmacology

Volumn 9, Issue 4, 1999, Pages 337-344

  Daniel, W A ^a   Syrek, M ^a   Wojcikowski J ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Fluoxetine; Fluvoxamine; Metabolism; Pharmacokinetic interaction; Promazine; Sertraline

Indexed keywords

CYTOCHROME B5; CYTOCHROME P450; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; PROMAZINE; SERTRALINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG INTERACTION; DRUG METABOLISM; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DRUG INTERACTIONS; MALE; PROMAZINE; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS;

EID: 0033152444     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(99)00006-1     Document Type: Article

References (37)

1. Baldessarini R.J., Cohen B.M., Teicher M.H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Gen. Psychiat. 45:1988;79-91.
2. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 31:1996;444-469.
3. Bhainre S., Bhagwat S.W., Shangar S.K., Boyd M.R., Ravindranath V. Flavin-containing monooxygenase mediated metabolism of psychoactive drugs by human brain microsomes. Brain Res. 672:1995;276-280.
4. Blake B.L., Rose R.L., Mailman R.B., Levi P.B., Hodgson E. Metabolism of thioridazine by microsomal monooxygenases: Relative roles of P-450 and flavin-containing monooxygenase. Xenobiotica. 25:1995;377-393.
5. Brøsen K., Skjelbo B., Rasmussen B.B., Poulsen H.B., Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45:1993;1211-1214.
6. Brøsen K., Zeugin T., Meyer U.A. Role of P4502D6, the target of the sparteine-debrisoquine oxidation polymorphism, in the metabolism of imipramine. Clin. Pharmacol. Ther. 49:1991;609-617.
7. Cashman J.R., Yang Z., Yang L., Wrighton S.A. Stereo- and regioselective N-oxidation and S-oxidation of tertiary amines and sulfides in the presence of adult human liver microsomes. Drug. Metab. Disposition. 21:1993;499-501.
8. Coutts R.T., Baker G.B., Daneshtalab M. Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line. Xenobiotica. 23:1993;1289-1298.
9. Crewe H.K., Lennard M.S., Tucker G.T., Woods F.R., Haddock R.B. The effect of selective re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver macrosomes. Br. J. Clin. Pharmacol. 34:1992;262-265.
10. Dahl M.L., Hall H. Binding activity of levomepromazine and two of its major metabolites to central dopamine and α-adrenergic receptors in the rat. Psychopharmacology. 74:1981;101-104.
11. Dahl-Puustinen M.L., Liden A., Alm C., Nordin C., Bertilsson L. Disposition of perphenazine is related to the polymorphic hydroxylation in human beings. Clin. Pharmacol. Ther. 46:1989;78-81.
12. Daniel W.A., Syrek M., Janczar L., Boksa J. The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats: A comparison with the pharmacokinetics of imipramine. Pol. J. Pharmacol. 47:1995;127-136.
13. Daniel W.A., Wójcikowski J. Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmarmacol. Toxicol. 80:1997;62-68.
14. Ghahramani P., Ellis S.W., Lennard M.S., Ramsay L.B., Tucker G.T. Cytochrome P450 mediating the N-demethylation of amitriptyline. Br. J. Clin. Pharmacol. 43:1997;137-144.
15. Goldenberg H., Fishman F., Heaton A. A detailed evaluation of promazine metabolism. J. Pharmacol. Exp. Ther. 150:1995;122-128.
16. Jeppesen U., Gram L.F., Vistisen K., Loft S., Poulsen H.B., Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. 51:1996;73-78.
17. Keck P.E., McElroy S.L., Strakowski S.M., West S.A. Pharmacologic treatment of schizoaffective disorder. Psychopharmacology. 114:1994;529-538.
18. Kobayashi K., Yamamoto T., Chiba K., Tani M., Ishizaki T., Kuroiwa Y. The effect of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br. J. Clin. Pharmacol. 40:(Suppl 5):1995;481-485.
19. Lane R. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. 11:(Suppl 5):1996;31-61.
20. Lemoine A., Gautier J.C., Azoulay D., Kiffel L., Belloc C., Guengerich F.P., Maurel P., Beaune P., Leroux J.P. Major pathway of imipramine metabolism is characterized by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol. Pharmacol. 43:1993;827-832.
21. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin fenol reagent. J. Biol. Chem. 193:1951;265-275.
22. Meyer J.W., Woggon B., Baumann P., Meyer U.A. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur. J. Clin. Pharmacol. 39:1990;613-614.
23. Midha K.K., Hubbard J.W., Marder S.R., Marshall B.D., Van Putten T. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J. Psychiatr. Neurosci. 19:1994;254-264.
24. Nelson J.C. Combined treatment strategies in psychiatry. J. Clin. Psychiat. 54:(Suppl 9):1993;42-49.
25. Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239:1964;2370-2378.
26. Omura T., Takesue S. A new method for simultaneous purification of cytochrome b and NADPH-cytochrome reductase from rat liver microsomes. J. Biochem. (Tokyo). 67:1970;249-257.
27. Ozdemir V., Naranjo C.A., Herrmann N., Reed K., Sellers B.M., Kalow W. Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo. Clin. Pharmacol. Ther. 62:1997;334-347.
28. Preskorn S. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clin. Pharmacokin. 32:(Suppl 1):1997;1-21.
29. Silver H., Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: An add-on double-blind, placebo-controlled study. Biol. Psychiat. 31:1992;698-704.
30. Skjelbo E., Brøsen K., Hallas J., Gram L.F. The mephenytoine oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin. Pharmacol. Ther. 49:1991;18-23.
31. Spina E., Steiner E., Ericsson Ö., Sjoqvist F. Hydroxylation of desmethylimipramine: dependence on debrisoquin hydroxylation phenotype. Clin. Pharmacol. 41:1987;314-319.
32. Sproule B.A., Naranjo C.A., Brenmer K.B., Hassan P.C. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin. Pharmacokinet. 33:1997;454-471.
33. Steiner E., Dumont E., Spina E., Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin. Pharmacol. Ther. 43:1988;577-581.
34. Syrek M., Wójcikowski J., Daniel W.A. Promazine pharmacokinetics during concurrent treatment with tricyclic antidepressants. Pol. J. Pharmacol. 49:1997;453-462.
35. Vergese C., Kessel J.B., Simpson G.M. Pharmacokinetics of neuroleptics. Psychopharmacol. Bull. 27:1991;551-563.
36. von Bahr C., Movin G., Nordin C., Liden A., Hammarlund-Udenaes M., Hedberg A., Ring H., Sjögvist F. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin. Pharmacol. Ther. 49:1991;234-240.
37. von Moltke L.L., Greenblatt D.J., Court M.H., Duan S.X., Harmatz J.S., Shader R.J. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. J. Clin. Psychopharmacol. 15:1995;125-131.